In silico resources help combat cancer drug resistance mediated by target mutations

Drug Discov Today. 2023 Sep;28(9):103686. doi: 10.1016/j.drudis.2023.103686. Epub 2023 Jun 27.

Abstract

Drug resistance causes catastrophic cancer treatment failures. Mutations in target proteins with altered drug binding indicate a main mechanism of cancer drug resistance (CDR). Global research has generated considerable CDR-related data and well-established knowledge bases and predictive tools. Unfortunately, these resources are fragmented and underutilized. Here, we examine computational resources for exploring CDR caused by target mutations, analyzing these tools based on their functional characteristics, data capacity, data sources, methodologies and performance. We also discuss their disadvantages and provide examples of how potential inhibitors of CDR have been discovered using these resources. This toolkit is designed to help specialists explore resistance occurrence effectively and to explain resistance prediction to non-specialists easily.

Keywords: Cancer; drug resistance; in silico; ligand-binding affinity; mutation.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Resistance, Neoplasm* / genetics
  • Humans
  • Mutation
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Proteins

Substances

  • Proteins